Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTpximpact Hldg Regulatory News (TPX)

Share Price Information for Tpximpact Hldg (TPX)

Share Price is delayed by 15 minutes
Get Live Data
69.00    6.00 (9.52%)
Bid:
68.00
Ask:
70.00
Spread: 2.00 (2.941%)
Market Cap: £65.39m
TPX Live PriceLast checked at - London Stock Exchange

Intraday Tpximpact Hldg Share Chart

Acquisition of Nudge Digital

1 Jul 2021 07:00

RNS Number : 7535D
Panoply Holdings PLC (The)
01 July 2021
 

This announcement contains inside information

1 July 2021

The Panoply Holdings PLC

("The Panoply", or the "Group")

 

Acquisition of Nudge Digital

The Panoply Holdings PLC, the technology-enabled services group focused on digital transformation, announces the acquisition of the entire issued and to be issued ordinary share capital of Nudge Digital Limited ("Nudge") (the "Acquisition"), a digital services agency which delivers strategy-led services primarily to the pharmaceutical industry, health sector and, more recently, to local authorities, with a particular focus around care pathways.

Bristol-based Nudge, founded in 2006 by CEO Luke Aikman, provides strategic consultancy and digital execution on mission-critical services, from global pharmaceutical projects to the software underpinning social housing and social care. Since its founding, Nudge has built up a strong client base including major pharmaceutical companies Roche and Galderma, private healthcare provider Bupa as well as the Greater London Authority, Hackney and Westminster councils.

The Acquisition is strategically important to the Group and strengthens its overall position in healthcare and, importantly, provides an entry into the pharmaceutical industry at a time when the NHS is looking at precision medicine, risk stratification and data-driven personalised care plans for patients.

The Acquisition is profitable and immediately earnings enhancing for The Panoply. Nudge has achieved significant revenue growth over the last two years of 151% and delivered revenues of £2.7m, adjusted EBITDA of £1.0m and adjusted profit after tax of £0.9m for the year ended 31 March 2021 (all unaudited). Nudge enters the group with a booked backlog of £2.5m for FY22.

The Panoply is paying a total consideration of £5.0m with £1.75m being satisfied in cash and £3.25m by the issue of new ordinary shares in The Panoply. The cash portion of the consideration will be funded through the Group's own cash reserves. The Group remains highly cash generative, with £4.9m net cash and a net debt position of £8.2m at 30 June, which remains at less than 1x pro forma EBITDA. 

 

Neal Gandhi, Chief Executive Officer of The Panoply, said:

"We're delighted to welcome Nudge to the Group at a time when the NHS is considering its approach to personalised healthcare and care pathways are coming into sharp focus as the government looks to deliver on its social care reform agenda.

Pulling together Nudge's experience in private healthcare and pharmaceuticals with the Group's existing experience across the NHS and local authority adult social care gives us a strong base to become a leader in the healthcare sector in the UK."

Luke Aikman, Chief Executive Officer of Nudge Digital, said:

"In recent months, Nudge has started to win contracts that are impactful and larger in size than ever before. By joining The Panoply, we can continue on that trajectory in the knowledge that we have a balance sheet that reassures our clients as well as a much larger team to draw upon to fulfill their requirements.

As a team, we're excited to begin working in collaboration with the rest of the Group and to continue delivering exceptional work to our client base."

 

Additional information on the acquisition

The Panoply has acquired all of the shares in Nudge Digital from Luke Aikman (CEO) and Jason Wilkes (Client Services Director).

The consideration payable under the share purchase agreement relating to the Acquisition (the "SPA") is £5m, subject to a completion accounts adjustment which is expected to result in the payment of approximately an additional £2.2m to Luke Aikman and Jason Wilkes in respect of excess cash in Nudge Digital. The consideration payable at completion of the Acquisition ("Completion") comprises the following:

(a) the allotment and issue of 1,190,476 new ordinary shares in The Panoply, with a value of £3.25m, calculated by reference to a price of 273 pence, being the 30 day average mid-market price on the day prior to announcement (the "Consideration Shares"); and

(b) a payment in cash of £1.75m.

together (the "Consideration").

The Consideration referred to in (b) above is being funded through the Group's existing cash reserves.

274,726 Consideration Shares or Consideration Shares with an aggregate value (based on the share price on the first anniversary of Completion) of £750,000 (whichever is higher) are released from lock-in on the first anniversary of Completion with the remainder of the Consideration Shares subject to lock-in arrangements until the third anniversary of Completion. Customary orderly market provisions apply for 12 months after each of the lock-in undertakings cease to apply.

Following the issue of the Consideration Shares, Luke Aikman and Jason Wilkes will hold 1,071,428 and 119,048 ordinary shares in The Panoply respectively, representing 1.4% in aggregate of the then issued share capital.

Admission and total voting rights

An application has been made for the admission of the Consideration Shares to trading on AIM which is expected to take place on or around 6 July 2021. Following this issue, the Company's issued share capital will comprise 82,571,502 Ordinary Shares and this is the total number of voting rights in the Company. There are no shares held in treasury.

This figure may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The person responsible for this announcement is Oliver Rigby, CFO.

Enquiries:

 

The Panoply Holdings

Neal Gandhi (CEO)

Oliver Rigby (CFO)

 

Stifel Nicolaus Europe Limited

(Nomad and Joint Broker)

 

Via Alma PR

 

 

+44 (0)207 710 7600

Fred Walsh

Alex Price

 

Dowgate Capital Limited

(Joint Broker)

James Serjeant

David Poutney

Nicholas Chambers

 

 

+44 (0)203 903 7715

Alma PR

(Financial PR)

Susie Hudson

Kieran Breheny

Matthew Young

panoply@almapr.co.uk

+44 (0)203 405 0209

 

About The Panoply

The Panoply is a technology-enabled services group, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

The Group is being increasingly recognised as a leading alternative digital transformation provider to the UK public services sector, with c.70% of its client base representing the public sector and c.30% representing the commercial sector.

More information is available at www.thepanoply.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQWPUUCQUPGPGU
Date   Source Headline
16th Jun 20267:00 amRNSUnaudited preliminary results
11th Jun 20267:00 amRNSShare Incentive Plan
1st Jun 20267:00 amRNSTPXimpact announces £16m contract with the MoJ
11th May 20267:00 amRNSShare Incentive Plan
22nd Apr 20267:00 amRNSFull Year Trading Update and Notice of Results
17th Apr 20264:17 pmRNSNotification of Major Holdings
17th Apr 20267:00 amRNSShare Incentive Plan
20th Mar 20267:00 amRNSShare Incentive Plan
24th Feb 20267:00 amRNSQ3 Trading Update: EBITDA guidance Upgrade
17th Feb 20267:00 amRNSContract Uplift
12th Feb 20267:01 amRNSTPXimpact announces £39m Contract with DEFRA
12th Feb 20267:00 amRNSShare Incentive Plan
11th Feb 20267:00 amRNSTPXimpact announces £22m NHS England contract
9th Jan 20267:00 amRNSShare Incentive Plan
9th Dec 20257:00 amRNSShare Incentive Plan
8th Dec 20255:19 pmRNSHolding(s) in Company
2nd Dec 20252:45 pmRNSExercise of Options, PDMR, & Total Voting Rights
2nd Dec 20257:00 amRNSUnaudited Interim Results
24th Nov 20257:30 amRNSAppointment of Nominated Adviser and Broker
14th Nov 20257:00 amRNSShare Incentive Plan
5th Nov 20257:00 amRNSFirst Half Update & Notice of Results
14th Oct 20255:29 pmRNSShare Incentive Plan
25th Sep 20254:37 pmRNSResult of AGM
9th Sep 20257:00 amRNSShare Incentive Plan
8th Sep 20255:25 pmRNSExercise of Options & PDMR Dealings
8th Sep 20253:27 pmRNSNotification of Major Holdings
5th Sep 202512:37 pmRNSIssuance of Shares & Total Voting Rights
22nd Aug 20257:00 amRNSNotice of AGM
21st Aug 20257:00 amRNSChange of Auditor
12th Aug 20256:05 pmRNSReplacement: FY25 & FY26 Share Awards
11th Aug 20257:00 amRNSPosting of Annual Report
4th Aug 20259:24 amRNSReplacement: FY25 & FY26 Share Awards
4th Aug 20257:00 amRNSFY25 & FY26 Long-Term Incentive Share Award
30th Jul 20257:00 amRNSDebt Facility Renewal Update
14th Jul 20257:00 amRNSAppointment of non-executive director
10th Jul 20257:00 amRNSShare Incentive Plan
24th Jun 20257:00 amRNSUnaudited preliminary results
16th Jun 20259:00 amRNSNotice of Results
12th Jun 20251:17 pmRNSShare Incentive Plan
14th May 20257:00 amRNSTrading Update and Contract Wins
22nd Apr 20257:00 amRNSResignation of Non-Executive Director
11th Apr 20257:00 amRNSShare Incentive Plan
12th Mar 20257:00 amRNSShare Incentive Plan
28th Feb 20253:26 pmRNSChange of Registered Office Address
12th Feb 20257:00 amRNSShare Incentive Plan
6th Feb 20257:00 amRNSQ3 Trading Update and Revised Outlook
3rd Feb 20257:00 amRNSConfirmation of CFO Appointment
15th Jan 20257:00 amRNSShare Incentive Plan
18th Dec 20247:00 amRNSDirectorate Change - Group CFO retirement
11th Dec 20247:00 amRNSShare Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.